Share Name Share Symbol Market Type Share ISIN Share Description
Omega Diagnostics Group Plc LSE:ODX London Ordinary Share GB00B1VCP282 ORD 4P
  Price Change % Change Share Price Shares Traded Last Trade
  0.325 10.0% 3.575 13,577,556 14:51:31
Bid Price Offer Price High Price Low Price Open Price
3.50 3.65 3.625 3.25 3.25
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 8.73 -35.40 -1.20 8
Last Trade Time Trade Type Trade Size Trade Price Currency
16:45:57 O 2,200,000 3.593 GBX

Omega Diagnostics (ODX) Latest News

More Omega Diagnostics News
Omega Diagnostics Investors    Omega Diagnostics Takeover Rumours

Omega Diagnostics (ODX) Discussions and Chat

Omega Diagnostics Forums and Chat

Date Time Title Posts
28/6/202221:11Omega Diagnostics - nicely poised for significant growth16,163
28/6/202217:14Omega Diagnostics Group Plc760
07/6/202214:06True Believers not traders2,085
25/5/202217:32Bullshit Free Zone630
25/5/202217:32Omega Diagnostics 2,333

Add a New Thread

Omega Diagnostics (ODX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2022-06-28 15:45:583.592,200,00079,046.00O
2022-06-28 15:44:513.592,200,00079,046.00O
2022-06-28 15:23:353.593,603,314129,467.07O
2022-06-28 15:21:493.6511,709427.20O
2022-06-28 15:20:473.592,200,00079,046.00O
View all Omega Diagnostics trades in real-time

Omega Diagnostics (ODX) Top Chat Posts

Omega Diagnostics Daily Update: Omega Diagnostics Group Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker ODX. The last closing price for Omega Diagnostics was 3.25p.
Omega Diagnostics Group Plc has a 4 week average price of 3.15p and a 12 week average price of 3.15p.
The 1 year high share price is 60.50p while the 1 year low share price is currently 3.08p.
There are currently 237,685,180 shares in issue and the average daily traded volume is 461,479 shares. The market capitalisation of Omega Diagnostics Group Plc is £8,497,245.19.
czar: ODX are owed money from this mob, £1+ I expect Abingdon Health plc ("Abingdon" or "the Company") Settlement agreement signed with the Department for Health and Social Care York, U.K. 28 June 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, notes recent bulletin board speculation and the rise in its share price. The Company confirms that it has reached a settlement agreement with the Department for Health and Social Care ("DHSC") on the outstanding invoices payable by DHSC for lateral flow tests and component stock. The Company notes that the settlement agreement only technically completes as and when the cash payment referred to below is received. The settlement agreement is in full and final settlement of the outstanding debt of £8.9m (excluding interest) and comprises: i) A contractually required cash payment of £6.3m from DHSC to Abingdon, which is required to be paid to the Company on or before 22 July 2022; £1.5m of this cash payment will be held under charge until the outcome of the judicial review is known; and ii) transfer to the Company of ownership of the outstanding component stock that it had procured on behalf of DHSC in 2020/1; and iii) joint-ownership, alongside DHSC, of the intellectual property of the AbC-19™ COVID-19 antibody test; and iv) a lower royalty payable to DHSC on sales of the AbC-19™ COVID-19 antibody test, with this royalty time limited to one year from the date of the settlement agreement. The monies received from DHSC, once received, will provide additional working capital and be deployed to help fund the Company's various growth initiatives underway.
arthur_lame_stocks: I'm not sure why you would want Omega to merge with Abingdon. Abingdon is an absolute dog of a company. AT least ODX has the decent Health & Nutrition business which IMO is worth twice the current price and CD4 may yet surprise us. I would like to see a complete change of BOD here though and a genuine focus on shareholder returns and strong financial management which has been sadly lacking for years.
elsssworth: ODX second bite of the cherry..covid cases rising again!!!..and Specials Madar chod mums pudis monkey puda pox disease.. Clearly ODX is the way forward. Level 4 target remains at 52p
specialmadarchodterimaakilan: ODX will soon be showing advancement in Rizzys mums monkey puda pox disease..also realigning the Covid testing kits.. Shares should start going up, up and up Rizzys aamis pudi to 52p
m1sterx: It is very unusual for a heavily traded and formally popular AIM stock to flatline for nearly two months like ODX has. Note how despised NCCL surged from .45p to 1.7p in a few days recently after the shares had flatlined, one suspects the 'bashers' of ODX are quietly going long ahead of a news-flow period, something to bear in mind, there has also been liquidity restraints on the offer, always a good sign. Time to go long ODX with a 10p target, would value the company around £18m, not demanding compared to peers, as pointed out by a few others if you know where to look. The astute are buyers.
hedgehog 100: What is a fair EV (enterprise value) valuation for ODX, before and after a bid. Well, IDH (Immunodiagnostic Systems Holdings) was taken over last May for c. £110M., an enterprise value of c. £88M. IDH's full year sales to 31.3.21 were £32.7M., and the H1 loss was about £3M. = An EV sales multiple of c. 2.7. Assuming full year ODX sales of say c. £12M., and applying a sales multiple of say c. 1.35, gives a value of c. £16M., or about 9p/share. I.e. well over double the current share price. And a bid could see that multiple moving much higher. That looks like a pretty good margin of safety to me, at the current share price of 3.85p. 17/05/2021 07:00 UK Regulatory (RNS & others) PerkinElmer Inc Offer for Immunodiagnostic Systems Holdings Plc LSE:IDH Immunodiagnostic Systems Holdings Plc " ...The boards of PerkinElmer, Inc. ("PerkinElmer") and Immunodiagnostic Systems Holdings PLC ("IDS") are pleased to announce that they have reached agreement on the terms of a recommended all cash offer whereby the entire issued and to be issued ordinary share capital of IDS will be acquired by PerkinElmer (UK) Holdings Limited ("PerkinElmer UK") (the "Acquisition"). -- Under the terms of the Acquisition, each IDS Shareholder will be entitled to receive: 382 pence in cash per IDS Share -- The Acquisition values the entire issued and to be issued ordinary share capital of IDS at approximately GBP110 million ($155 million), on the basis of a fully diluted share capital of 28,865,469 IDS Shares. This implies an enterprise value of IDS of approximately GBP88 million ($124 million). -- The price of 382 pence in cash per IDS Share represents a premium of approximately: -- 49.8 per cent. to the Closing Price of 255 pence per IDS Share on the Last Practicable Date; -- 58.1 per cent. to the Volume Weighted Average Price per IDS Share during the one month period ended on the Last Practicable Date; -- 68.2 per cent. to the Volume Weighted Average Price per IDS Share during the three month period ended on the Last Practicable Date; and -- 72.5 per cent. to the Volume Weighted Average Price per IDS Share during the five year period ended on the Last Practicable Date. ..."
kirk 6: Any sort of alternative finance or a deal announced with send share price multiply higher. As we haven't got a huge amount of shares to trudge through from a placing.Any news now could send this 1000% higher
hedgehog 100: ODX's Heath & Nutrition business seems to be growing like gangbusters! Not only a 62% H1 increase in sales, to £4.17M. But then ODX has recently expressed confidence that this business would see significant further growth in H2, i.e. in the half ending in just a few days. What a quite stunning performance during a pandemic! Moreover, based ODX's total H1 revenue of £5.73M., which was a whopping 81% increase, ODX's annualised revenue is £11.46M., (i.e. not allowing for H2 growth). At it's current market cap. of about £11.7M. at 4p, and that puts ODX on an annualised price-to-sales ratio of barely one. Compare that to GDR: full year sales of a paltry £0.7M., a fall on the revious year, but a current market cap. of £27M. at 29.25p 25/11/2021 07:00 UK Regulatory (RNS & others) Omega Diagnostics Group PLC Half-year Report LSE:ODX Omega Diagnostics Group Plc "Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products, announces its unaudited interim results for the six months ended 30 September 2021. Omega has substantial growth opportunities in the areas of Food Sensitivity, CD4 testing for the management of people living with HIV, and COVID-19 antibody and antigen testing and provides high quality in-vitro diagnostics products for use in hospitals, clinics, laboratories and healthcare practices in over 75 countries. Financial Highlights: -- Revenue increased by 81% to GBP5.73m (H1 '20: GBP3.16m) -- Health and Nutrition sales up 62% to GBP4.17m (H1 '20: GBP2.58m) -- Global Health revenue up 170% to GBP1.56m (H1 '20: GBP0.58m) ..." 09/11/2021 07:00 UK Regulatory (RNS & others) Genedrive PLC Final Results LSE:GDR Genedrive Plc "genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces its audited Final Results for the year ended 30 June 2021. Financial Highlights -- Revenue for the year to 30 June 2021 GBP0.7m (2020: GBP1.1m) -- Loss for the year of GBP0.7m (2020: GBP19.4m loss) ..."
hedgehog 100: ODX recently expressed confidence that its Health and Nutrition business would see significant H2 growth, i.e. in the half ending in just a few days. And an update on their new strategy is also due shortly. In addition, ODX meeting the 31st. March deadline for its self-test CE Mark data would also improve confidence here. 11/02/2022 07:00 UK Regulatory (RNS & others) Omega Diagnostics Group PLC Fundraising to raise gross proceeds of up to GBP7m LSE:ODX Omega Diagnostics Group Plc " ... Jag Grewal, CEO of Omega, commented: "Having already announced the first stage of our planned strategy to improve sales performance across the Group and to reduce losses, the transfer of our Alva site to Orient Gene and this fundraise delivers the additional capital for Omega to drive growth in our Health & Nutrition division. At the conclusion of our planned strategic review of CD4, the funding provides us with the potential opportunity to relocate our CD4 production to our new Ely site and improve operational efficiencies. "I would like to put on record my thanks to new and existing shareholders for their support and we look forward to updating the market with regards our new strategy in the months ahead." ... The Company remains focused on improving operational efficiencies and sensibly controlling costs. The Company is confident that revenues in the second half will see significant growth in both Health and Nutrition and for its CD4 product, whilst COVID-19 revenues are now likely to be minimal given the delays in gaining CTDA approval for the Company's professional antigen test and the very recent CE-marking of the antigen self-test. Overall, the Company believes that it will see an improved sales performance across the Group for the full year as compared with the year ended 31 March 2021 and to see trading losses slightly reduced in the second half." 11/03/2022 07:00 UK Regulatory (RNS & others) Omega Diagnostics Group PLC Update on validation under CTDA legislation LSE:ODX Omega Diagnostics Group Plc " ... The Directors believe that the self-test market is much more relevant in terms of opportunity and Omega continues to work closely with its external study centres to ensure the 31 March 2022 deadline is met for the submission of the outstanding self-test CE Mark data. Jag Grewal, CEO of Omega, commented: "Whilst this is clearly disappointing, our plans do not include any contribution from COVID-19 antigen tests, as we focus the business on driving growth in our Health & Nutrition division."" Genedrive (GDR):
sanks: SpecialGypo.. My nob is next to the Christmas tree..feel free to stroke it on the way out..thank you. ..or you might want to consider ODX as the skirt is lifted towards £1.10 and above.. Just look at GDR today!!!..ODX share price was hand in hand with GDR this is an easy £1.10 target!! 30.00 GBX +13.75 (84.62%)today 18 Mar, 16:06 GMT
Omega Diagnostics share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Omega Diag..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220629 04:23:09